# Chengdu Zenitar Biomedical Technology

Source: https://onco.cc/companies/chengdu-zenitar-biomedical-technology/  
OnCo record `chengdu-zenitar-biomedical-technology` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Chengdu Zenitar Biomedical Technology is a Chinese developer in Chengdu that sponsors 6 registered cancer trials of Purinostat and Purinostat Mesylate.

## Summary

Chengdu Zenitar Biomedical Technology appears on ClinicalTrials.gov as the industry sponsor of 6 interventional cancer trials (phase 1/2, 2, 3), testing Purinostat, Purinostat Mesylate, Selinexor, Flonoltinib in advanced solid tumor, recurrent and refractory diffuse large b-cell lymphoma, diffuse large b cell lymphoma，dlbcl, polycythemia vera (pv). OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Chengdu Zenitar Biomedical Technology Co., Ltd
- Tags: ctgov-sponsor; china; registry-only
- HQ: Chengdu, China
- Type: biotech

## Sources

- ClinicalTrials.gov: trials sponsored by Chengdu Zenitar Biomedical Technology: https://clinicaltrials.gov/search?spons=Chengdu%20Zenitar%20Biomedical%20Technology

## Connected records

- trials: [A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06431243/), [A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma](https://onco.cc/trials/nct06485219/), [A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma](https://onco.cc/trials/nct07011056/), [Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera](https://onco.cc/trials/nct07232290/), [Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct06484829/), [Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)](https://onco.cc/trials/nct05563844/)

---
JSON: https://onco.cc/api/v1/entities/chengdu-zenitar-biomedical-technology.json